BiotechTube
AvenCell Therapeutics

AvenCell Therapeutics

Munich, Germany· Est.
avencell.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $60M

Overview

AvenCell Therapeutics is a German biotech launched in 2020 with a $250 million commitment from Blackstone Life Sciences, formed by integrating GEMoaB GmbH and licensing technology from Intellia Therapeutics. The company is advancing a pipeline of autologous and allogeneic universal reprogrammable T cell products based on its core platforms: a switchable CAR system and a CRISPR/Cas9-based allogeneic platform. AvenCell aims to address a significant market opportunity in oncology by improving the therapeutic window and safety profile of cell therapies for cancers with high unmet need.

Oncology

Technology Platform

Proprietary Universal Switchable CAR platform (combining a universal effector cell with soluble Targeting Modules for on/off control) and a licensed CRISPR/Cas9-based allogeneic platform for creating off-the-shelf cell therapies.

Funding History

1
Total raised:$60M
Series A$60M

Opportunities

The primary opportunity is addressing the massive unmet need in solid tumors and improving upon first-generation CAR-T therapies in hematological cancers, targeting a market exceeding $50B.
The switchable technology could enable safer, more controllable treatments, potentially expanding treatable patient populations and enabling combination regimens.

Risk Factors

Key risks include the clinical and technical uncertainty of novel, complex platform technologies, particularly in achieving efficacy in solid tumors and managing allogeneic cell persistence/rejection.
The company also faces intense competition in the next-generation CAR-T space and execution risks associated with integrating acquired assets and teams.

Competitive Landscape

AvenCell competes in the rapidly evolving next-generation CAR-T space, facing numerous companies developing allogeneic (e.g., Allogene, Cellectis, Precision BioSciences) and/or controllable/switched CAR-T platforms (e.g., Bellicum Pharmaceuticals, Autolus). Its differentiation lies in combining switchability with an allogeneic approach, aiming for superior safety and scalability.

More companies in Cell & Gene Therapy →More companies in Germany →